Skip to main content
. Author manuscript; available in PMC: 2020 Sep 3.
Published in final edited form as: Breast Cancer Res Treat. 2019 May 22;176(3):709–716. doi: 10.1007/s10549-019-05264-2

Table 2.

Neoadjuvant chemotherapy with associated clinical responses and outcomes

ID 1st NAC Number of cycles (total weeks) Clinical response 2nd NAC (if any) Number of cycles (total weeks) Clinical response Final surgery (RCB) Local/distant relapse Time to relapse (months)
Progression to metastatic disease
1 TP Two cycles (8 weeks due to delays for concern of abscess) Initial clinical improvement, but radiographic progression and pulmonary metastatic disease on CT chest None N/A Yes 0
2 AC (dd) Four cycles (10 weeks due to delays) Partial radiographic response on breast MRI TP Three cycles (11 weeks due to delays) No response on CT chest N/A Yes 0
Clinical or radiographic progression on any NAC
3a T+Hsp90 inhibitoi 1.5 cycles (5 weeks) No radiographic response on breast MRI TP Three cycles (10 weeks due to delays) Clinical and radiographic progression on breast MRI III Yes 1.5
4b AC Four cycles (12 weeks) Partial radiographic response on CT chest TP Three cycles (9 weeks) Clinical progression III Yes 8
5c AC Two cycles (6 weeks) Clinical progression None II Unknown
No response or unknown response
6b TAC Six cycles (18 weeks) Unknown None Not available Yes 4
7 AC (dd) Four cycles (8 weeks) Unknown TP Four cycles (8 weeks) Unknown Not available Yes 11
8 AC +vincristine Four cycles (8 weeks) Partial response by breast MRI TP Four cycles (12 weeks) Unknown II Yes 14
9 AC (dd) Four cycles (9 weeks due to delays) Unknown T
TP
One cycle (3 weeks)
One cycle (3 weeks)
Unknown II None -
10a TP4 Four cycles (12 weeks) Minimal radiographic improvement on breast ultrasound None II Unknown
11 TP Four cycles (12–13 weeks due to delays) Partial radiographic response on breast ultrasound AC (dd) Four cycles (8 weeks) Unknown II None
12e T One cycle (3 weeks) Radiographic progression on breast MRI AC (dd) Four cycles (8 weeks) No response on MRI II None -
TP Four cycles (12 weeks) Clinical and radiographic improvement on breast MRI
Radiographic or clinical improvement
13 TC Four cycles (12 weeks) Radiographic improvement on breast MRI None II Yes 10
14f T + Herceptin Four cycles (12 weeks) Radiographic improvement None Not available None -
15 AC (dd) Four cycles (8 weeks) Clinical improvement TP Four cycles (8 weeks) Clinical and radiographic improvement on PET-CT Not available Unknown
16 AC (dd) Four cycles (8 weeks) Radiographic improvement on breast MRI T (dd) Four cycles (9 weeks due to delay) Clinical improvement I None -
Complete pathological response
17e AC (dd) Four cycles (8 weeks) Clinical and radiographic improvement on breast MRI T (dd) Four cycles (8 weeks) Radiographic improvement on mammogram 0 None -
18 TP Four cycles (12 weeks) Complete radiographic response on breast MRI AC (dd) Four cycles (8 weeks) Complete response on breast MRI 0 None -

A anthracycline-based therapy, C cyclophosphamide-based therapy, T Taxane-based therapy, P Platinum-based therapy, dd dose-dense

a

Received adjuvant AC

b

Received adjuvant hormonal therapy

c

Received adjuvant TP

d

Clinical trial J0785-Carboplatin/nab-paclitaxel/vorinostat

e

Received adjuvant capecitabine

f

Tumor is HER-2 + and patient received 1 year adjuvant Herceptin